1 min read
Stifel Upgrades Tandem to Buy and Downgrades Insulet on Pump Trends
Stifel linked both rating moves to survey results indicating recent trends in tubeless insulin pumps.

Stifel upgraded Tandem Diabetes Care (TNDM) to Buy from Hold and downgraded Insulet Corporation (PODD), linking the moves to survey results indicating recent trends in the tubeless insulin-pump market.
The rating actions came after the U.S. Food and Drug Administration (FDA) cleared a tubeless version of Tandem’s Mobi insulin-delivery system.